Technical Analysis for RYTM - Rhythm Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 22.08 -0.59% -0.13
RYTM closed up 1.51 percent on Tuesday, November 19, 2019, on 69 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical RYTM trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish -0.59%
MACD Bullish Centerline Cross Bullish -0.59%
Pocket Pivot Bullish Swing Setup -0.59%
Bollinger Band Squeeze Range Contraction -0.59%
BB Squeeze Started Range Contraction -0.59%
BB Squeeze + Upper Band Touch Range Contraction -0.59%
Gapped Up Strength -0.59%
Up 3 Days in a Row Strength -0.59%
Up 4 Days in a Row Strength -0.59%
Upper Bollinger Band Touch Strength -0.59%

Older signals for RYTM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
Biopharmaceutical Medical Specialties Organ Systems Obesity Peptide Hormones Peptides Metabolic Disorders
Is RYTM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.94
52 Week Low 18.0
Average Volume 241,848
200-Day Moving Average 24.0654
50-Day Moving Average 21.9251
20-Day Moving Average 21.5895
10-Day Moving Average 21.548
Average True Range 0.9048
ADX 9.59
+DI 25.3887
-DI 19.1183
Chandelier Exit (Long, 3 ATRs ) 21.9456
Chandelier Exit (Short, 3 ATRs ) 23.1844
Upper Bollinger Band 22.4714
Lower Bollinger Band 20.7076
Percent B (%b) 0.85
BandWidth 8.169712
MACD Line 0.0456
MACD Signal Line -0.0334
MACD Histogram 0.079
Fundamentals Value
Market Cap 579.11 Million
Num Shares 26.1 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -7.10
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.40
Resistance 3 (R3) 23.43 23.07 23.20
Resistance 2 (R2) 23.07 22.77 23.05 23.13
Resistance 1 (R1) 22.64 22.58 22.86 22.61 23.07
Pivot Point 22.28 22.28 22.39 22.26 22.28
Support 1 (S1) 21.85 21.98 22.07 21.82 21.35
Support 2 (S2) 21.49 21.79 21.47 21.29
Support 3 (S3) 21.06 21.49 21.22
Support 4 (S4) 21.03